Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
Three-year data – with a median follow-up of 44 months – from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib ...
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma in ...
Combination treatment with immune checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor types such as melanoma. The open-label, parallel-cohort, ...
South Korea's exports extended their growth streak to a ninth month in February as strong chip sales continued to underpin overall shipments even as uncertainties regarding U.S. tariffs cloud the ...
Two Sealed Airtight Medical Vials Against Bright Background Front View. Findings from the phase 3 international CheckMate 901 trial called “a momentous accomplishment.” Combination therapy with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results